*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Sunho Biologics, Inc.**

**盛禾生物控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2898)**

# APPOINTMENT OF CHIEF EXECUTIVE OFFICER AND CHIEF SCIENTIFIC OFFICER

The board (the "**Board**") of directors (the "**Directors**" and each a "**Director**") of Sunho Biologics, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces that, with effect from 23 January 2026, Ms. JIANG Xiaoling (姜曉玲), an executive Director, has been appointed as the chief executive officer (the "**Chief Executive Officer**") and the chief scientific officer (the "**Chief Scientific Officer**") of the Company (the "**Appointment**").

For the biographical details, interests in and positions held with the Group, terms of appointment as Director of Ms. Jiang Xiaoling, please refer to the annual report of the Company dated 29 April 2025. As of the date of this announcement, there has been no change in such information. Ms. Jiang Xiaoling has entered into a service contract with the Company for her role as an executive Director. No specific service contract will be entered into in respect of her appointment as the Chief Executive Officer and Chief Scientific Officer. The remuneration was determined and recommended based on her personnel's experience and qualifications, level of responsibility, performance and the time devoted to the business, and the prevailing market conditions. The amount shall be disclosed in the Company's annual report during her term of office.

Reference is made to the announcement of the Company dated 19 January 2026, in relation to, the resignation of Dr. YIN Liusong (殷劉松) ("**Dr. Yin**") as an executive Director, the Chief Executive Officer and Chief Scientific Officer (the "**Resignation**") with effect from 28 February 2026. For the avoidance of doubt, Ms. Jiang Xiaoling and Dr. Yin will carry out the responsibilities and duties of the Chief Executive Officer and Chief Scientific Officer jointly before the Resignation takes effect on 28 February 2026.

Saved as disclosed above and as of the date of this announcement, Ms. Jiang Xiaoling does not have: (a) any positions held with the Company and other members of the Group; (b) any directorships held in the last three years in public companies the securities of which are listed on any securities market in Hong Kong or overseas; (c) any relationships with any Directors, senior management or substantial or controlling shareholders of the Company; and (d) any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Save as disclosed above, the Board is not aware of any other matters in relation to the Appointment that need to be brought to the attention of the shareholders of the Company and there is no information which is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board would like to express its warm welcome to Ms. Jiang Xiaoling for her new appointment.

By order of the Board
**Sunho Biologics, Inc.**
**Mr. ZHANG Feng**
*Chairman and executive Director*

Hong Kong, 23 January 2026

*As of the date of this announcement, the executive Directors are Mr. ZHANG Feng, Dr. YIN Liusong and Ms. JIANG Xiaoling; the non-executive Director is Mr. FAN Rongkui; and the independent non-executive Directors are Mr. CHAN Heung Wing Anthony, Ms. FENG Lan and Mr. SHI Luwen.*